China Medical's SPR molecular diagnostic system approved in China
This article was originally published in Clinica
The Chinese state FDA (SFDA) has approved China Medical Technologies' surface plasmon resonance (SPR)-based biosensor system. The technology, which has been used in molecular diagnostics research for 20 years, has potential in several clinical diagnostic applications, including detecting biomarkers for infectious diseases, cancers, and cardiovascular and immune system disorders. For example, the SPR system can detect human papillomavirus (HPV), and can be used in combination with fluorescence in situ hybridisation (FISH) to identify patients with early-stage cervical cancer, said the firm. The system has been designed for high throughput and speed, is highly automated, and can display results in real time and online. Beijing-based China Medical has begun delivering the system to "large hospital customers".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.